{"meshTags":["Humans","Sulfonamides","Melanoma","Proto-Oncogene Proteins B-raf","Animals","Drug Resistance, Neoplasm","Indoles"],"meshMinor":["Humans","Sulfonamides","Melanoma","Proto-Oncogene Proteins B-raf","Animals","Drug Resistance, Neoplasm","Indoles"],"genes":["BRAF kinase","BRAF(V600E) mutation"],"publicationTypes":["News"],"abstract":"In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.","title":"Vemurafenib.","pubmedId":"22037033"}